Human Liver Cancer Cell Hep-3B Transfection Kit
| Kit size Volume | Quantity | ||
|---|---|---|---|
| 1.5 ml CRISPR(Cat-215232) | Inquiry | Add to cart | |
| 0.5 ml(Cat-681730) | Inquiry | Add to cart | |
| 1.5 ml(Cat-681831) | Inquiry | Add to cart | |
| 8.0 ml(Cat-681933) | Inquiry | Add to cart |
Description
Product Information
Modes of administration
Reagent exhibits at least 78% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Description
Hep3B is a well-known human liver cancer cell line derived from a patient with a well-differentiated hepatocellular carcinoma. It has become a widely used model system for investigating various aspects of liver cancer biology, including tumor growth, invasion, metastasis, and drug resistance. Hep3B cells are highly resistant to conventional chemotherapeutic drugs, making them a valuable tool for studying drug resistance mechanisms and developing new cancer therapies. Researchers also use Hep3B cells to explore the molecular mechanisms underlying liver cancer development and progression, as well as to identify potential therapeutic targets and biomarkers of the disease.
CD BioSciences offers nanoparticle-based transfection reagent kits designed for the Hep-3B hepatoma cell line, which yield high transfection efficiency. These kits are an essential tool for researchers working with Hep3B cells to investigate liver cancer biology and drug resistance.
